Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4
1(33.3%)
N/A
1(33.3%)
Phase 3
1(33.3%)
3Total
Phase 4(1)
N/A(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00415493Not ApplicableCompleted

Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation

Role: lead

NCT00980707Phase 4Completed

Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma

Role: lead

NCT00214552Phase 3Completed

Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.

Role: lead

All 3 trials loaded